Abbvie Stock Surges 1.88% on 12.56 Billion Trading Volume Ranking 64th Amid Legal Battles and Competition

Abbvie(ABBV) on April 23, 2025, recorded a trading volume of 12.56 billion, ranking 64th in the day's stock market. The company's stock price rose by 1.88%, marking the second consecutive day of gains, with a total increase of 4.05% over the past two days.

Abbvie has recently been in the spotlight due to its ongoing legal battles. The company is currently facing a lawsuit from the U.S. Department of Justice, which alleges that Abbvie has been overcharging for its blockbuster drug, Humira. The lawsuit claims that Abbvie has been using patent thickets and other tactics to maintain its monopoly on the drug, which has resulted in higher prices for consumers.

In addition to the legal challenges, Abbvie is also facing increased competition in the biopharmaceutical industry. The company's patent on Humira is set to expire in 2023, which will allow generic versions of the drug to enter the market. This could potentially lead to a significant decrease in Abbvie's revenue from Humira, which currently accounts for a large portion of the company's total revenue.

Despite these challenges, Abbvie has been taking steps to diversify its portfolio and reduce its reliance on Humira. The company has been investing in research and development for new drugs and has recently acquired several smaller biopharmaceutical companies. These acquisitions have allowed Abbvie to expand its product offerings and enter new markets, which could help to offset the potential loss of revenue from Humira.

Overall, while Abbvie is facing significant challenges in the near term, the company's long-term prospects remain strong. The company's diversified portfolio and ongoing investments in research and development position it well to continue to grow and thrive in the competitive biopharmaceutical industry.